VXRT Vaxart, Inc.
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
Company profile
Ticker
VXRT
Exchange
Website
CEO
Wouter W. Latour
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Amgen • Gilead Sciences • Biogen • Qiagen • Moderna • Acorda Therapeutics • Bio-Techne • PDL BioPharma • BioNTech SE • Denali Therapeutics ...
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., Nabi Biopharmaceuticals, Nabi, Nabi Biopharmaceuticals, North American Biologicals Inc
SEC CIK
Corporate docs
IRS number
591212264
VXRT stock data
()
Calendar
12 Nov 19
10 Dec 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Sep 19 | Jun 19 | Mar 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | 454K | 85K | 5.41M | 1.77M | |
| Net income | -5.26M | -5.64M | -1.34M | -4.9M | |
| Diluted EPS | -0.32 | -0.39 | -0.18 | -0.69 | |
| Net profit margin | -1159% | -6632% | -24.76% | -277% | |
| Operating income | -4.71M | -5M | -448K | -4.19M | |
| Net change in cash | 3.3M | 7.88M | -3.08M | -6.48M | |
| Cash on hand | 19.54M | 16.24M | 8.36M | 11.44M | |
| Cost of revenue |
| Annual (USD) | Dec 18 | Dec 17 |
|---|---|---|
| Revenue | 4.16M | 5.84M |
| Net income | -18.01M | -9.58M |
| Diluted EPS | -2.9 | -91.65 |
| Net profit margin | -433% | -164% |
| Operating income | -21.76M | -10.02M |
| Net change in cash | 9.87M | |
| Cash on hand | 11.44M | 1.57M |
| Cost of revenue |
Financial data from Vaxart earnings reports
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
addressing, ahead, arm, Armistice, ASC, charter, cohort, coincide, composed, confirmation, expiry, hedge, liter, Master, MSA, nominating, orange, peak, regularly, repaid, robust, RPO, shareholder, SOW, unbilled, unsolicited
Removed:
affiliated, anti, August, bankruptcy, collateralized, disseminate, flexibility, IgG, kickback, maturity, nonroutine, optimization, possession, responded, serum, venture
Financial reports
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
6 Feb 19
10-Q
2018 Q3
Quarterly report
13 Nov 18
10-Q
2018 Q2
Quarterly report
10 Aug 18
10-Q
2018 Q1
Quarterly report
15 May 18
10-Q
2018 Q2
Quarterly report
6 Feb 18
10-Q
2018 Q1
Quarterly report
7 Nov 17
10-K/A
2017 FY
Annual report (amended)
20 Oct 17
Current reports
8-K
Departure of Directors or Certain Officers
4 Dec 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Nov 19
8-K
Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update
12 Nov 19
8-K
Termination of a Material Definitive Agreement
7 Nov 19
8-K
Departure of Directors or Certain Officers
28 Oct 19
8-K
Other Events
25 Sep 19
8-K
Entry into a Material Definitive Agreement
19 Sep 19
8-K
Vaxart Announces Second Quarter 2019 Financial Results
8 Aug 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 May 19
8-K
Departure of Directors or Certain Officers
16 May 19
Registration and prospectus
424B4
Prospectus supplement with pricing info
27 Sep 19
POS AM
Prospectus update (post-effective amendment)
27 Sep 19
FWP
Free writing prospectus
25 Sep 19
S-1/A
IPO registration (amended)
24 Sep 19
S-1/A
IPO registration (amended)
20 Sep 19
S-1
IPO registration
11 Sep 19
S-8
Registration of securities for employees
24 Apr 19
424B4
Prospectus supplement with pricing info
10 Apr 19
POS AM
Prospectus update (post-effective amendment)
10 Apr 19
S-1/A
IPO registration (amended)
8 Apr 19
Proxies
DEFA14A
Additional proxy soliciting materials
11 Mar 19
DEF 14A
Definitive proxy
11 Mar 19
PRE 14A
Preliminary proxy
28 Feb 19
DEF 14A
Definitive proxy
26 Feb 18
DEFA14A
Additional proxy soliciting materials
26 Feb 18
DFAN14A
Additional proxy materials by non-management
9 Feb 18
DFAN14A
Additional proxy materials by non-management
31 Jan 18
DFAN14A
Additional proxy materials by non-management
29 Jan 18
DFAN14A
Additional proxy materials by non-management
24 Jan 18
DEFC14A
Proxy in contested situation
23 Jan 18
Other
EFFECT
Notice of effectiveness
3 Oct 19
EFFECT
Notice of effectiveness
27 Sep 19
EFFECT
Notice of effectiveness
11 Apr 19
EFFECT
Notice of effectiveness
9 Apr 19
CORRESP
Correspondence with SEC
8 Apr 19
CORRESP
Correspondence with SEC
8 Apr 19
EFFECT
Notice of effectiveness
18 Mar 19
EFFECT
Notice of effectiveness
29 Dec 17
CORRESP
Correspondence with SEC
28 Dec 17
UPLOAD
Letter from SEC
20 Dec 17
Ownership
SC 13D/A
Vaxart, Inc.
22 Nov 19
SC 13D/A
Vaxart, Inc.
1 Nov 19
SC 13D/A
Vaxart, Inc.
8 Oct 19
SC 13D
Vaxart, Inc.
1 Oct 19
SC 13G
Vaxart, Inc.
25 Apr 19
SC 13G
Vaxart, Inc.
17 Apr 19
SC 13D
Vaxart, Inc.
23 Feb 18
SC 13G
Aviragen Therapeutics, Inc.
15 Feb 18
SC 13G
Aviragen Therapeutics, Inc.
14 Feb 18
SC 13D/A
Aviragen Therapeutics, Inc.
13 Feb 18